Navigation Links
Bio-AMD, Inc.; Legal Action Settled
Date:12/8/2011

LONDON, Dec. 8, 2011 /PRNewswire/ -- Bio-AMD, Inc. ("Bio-AMD" or the "Company) (OTCBB: BIAD) today announces settlement of a claim against its former legal counsel.

The Company is pleased to have satisfactorily settled its claim prior to a timetabled court hearing in 2012 which would otherwise have resulted in further cost, distraction and risk to its business. The Company now looks forward to further progressing its core medical diagnostic device operations.

About Bio-AMD, Inc.

Bio-AMD has two majority owned UK subsidiaries: Bio-AMD Limited, a technology developer for medical diagnostic devices; and the WDX Organisation Ltd, the owner of the Wocu™, a global currency data reference source for application in financial markets. (www.wocu.com).

To find out more about Bio-AMD (OTCBB: BIAD), visit our websites at www.bioamd.com.

Forward-Looking Statements

Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties.  Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import.  Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management.  Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company.  Readers are cautioned not to place undue reliance on such forward-looking statements.  Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 filed on March 23, 2011.  Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

CONTACT:  Bio-AMD, Inc.
Tom Barr, CEO
+44 (0)8445 861 910


'/>"/>
SOURCE Bio-AMD, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Smith & Nephew Inc. Acquires Privately-Held TENET Medical Engineering, Inc.; Premier Provider of Surgical Patient Positioning Equipment
2. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
3. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
4. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
5. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
6. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
7. Alabama Stop-Sale System Blocks Illegal Sales & Allows Legal Ones
8. PharmAthene Submits Legal Brief in Response to SIGA Technologies Motion for Reargument
9. NADDI Lauds Ohio Bill Introduction: Real-Time, Stop-Sale System Blocks Illegal Sales
10. CMUs Nicolas Christin Finds Web Hackers Profiting From Illegal Online Pharmacies
11. Avanir Pharmaceuticals Announces Appointment of Elona Kogan, Esq. as Vice President of Legal Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... name the Creator responds to and which He does not. Yisrayl says with so ... one is the true name, but he says with a little Scripture, backed with a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA ... region. Côté has 20+ years of experience within the beauty industry, ranging from ... an array of high-end cosmetic brands, retail brands and outlets in Canada and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Christie Medical Holdings, Inc. ... alliance with B. Braun Medical Inc. , a leader in infusion therapy and ... with as many as 90 percent of hospital patients receiving a peripheral IV catheter ...
Breaking Medicine News(10 mins):